Cryopreservation of Hematopoietic Stem Cells

Emerging Assays, Cryoprotectant Agents, and Technology to Improve Outcomes

Kathlyn M Hornberger, Guanglin Yu, David H McKenna, Allison Hubel

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Hematopoietic stem cell (HSC) therapy is widely used to treat a growing number of hematological and non-hematological diseases. Cryopreservation of HSCs allows for cells to be transported from the site of processing to the site of clinical use, creates a larger window of time in which cells can be administered to patients, and allows sufficient time for quality control and regulatory testing. Currently, HSCs and other cell therapies conform to the same cryopreservation techniques as cells used for research purposes: cells are cryopreserved in dimethyl sulfoxide (DMSO) at a slow cooling rate. As a result, HSC therapy can result in numerous adverse symptoms in patients due to the infusion of DMSO. Efforts are being made to improve the cryopreservation of HSCs for clinical use. This review discusses advances in the cryopreservation of HSCs from 2007 to the present. The preclinical development of new cryoprotectants and new technology to eliminate cryoprotectants after thawing are discussed in detail. Additional cryopreservation considerations are included, such as cooling rate, storage temperature, and cell concentration. Preclinical cell assessment and quality control are discussed, as well as clinical studies from the past decade that focus on new cryopreservation protocols to improve patient outcomes.

Original languageEnglish (US)
Pages (from-to)188-196
Number of pages9
JournalTransfusion Medicine and Hemotherapy
Volume46
Issue number3
DOIs
StatePublished - Jun 1 2019

Fingerprint

Colony-Forming Units Assay
Cryopreservation
Hematopoietic Stem Cells
Technology
Cell- and Tissue-Based Therapy
Dimethyl Sulfoxide
Quality Control
Temperature
Research

Keywords

  • Cryopreservation
  • Dimethyl sulfoxide
  • Freezing
  • Hematopoietic stem cells
  • Storage

PubMed: MeSH publication types

  • Journal Article
  • Review

Cite this

Cryopreservation of Hematopoietic Stem Cells : Emerging Assays, Cryoprotectant Agents, and Technology to Improve Outcomes. / Hornberger, Kathlyn M; Yu, Guanglin; McKenna, David H; Hubel, Allison.

In: Transfusion Medicine and Hemotherapy, Vol. 46, No. 3, 01.06.2019, p. 188-196.

Research output: Contribution to journalReview article

@article{3769501aa0da490ba6d0e37812f425b1,
title = "Cryopreservation of Hematopoietic Stem Cells: Emerging Assays, Cryoprotectant Agents, and Technology to Improve Outcomes",
abstract = "Hematopoietic stem cell (HSC) therapy is widely used to treat a growing number of hematological and non-hematological diseases. Cryopreservation of HSCs allows for cells to be transported from the site of processing to the site of clinical use, creates a larger window of time in which cells can be administered to patients, and allows sufficient time for quality control and regulatory testing. Currently, HSCs and other cell therapies conform to the same cryopreservation techniques as cells used for research purposes: cells are cryopreserved in dimethyl sulfoxide (DMSO) at a slow cooling rate. As a result, HSC therapy can result in numerous adverse symptoms in patients due to the infusion of DMSO. Efforts are being made to improve the cryopreservation of HSCs for clinical use. This review discusses advances in the cryopreservation of HSCs from 2007 to the present. The preclinical development of new cryoprotectants and new technology to eliminate cryoprotectants after thawing are discussed in detail. Additional cryopreservation considerations are included, such as cooling rate, storage temperature, and cell concentration. Preclinical cell assessment and quality control are discussed, as well as clinical studies from the past decade that focus on new cryopreservation protocols to improve patient outcomes.",
keywords = "Cryopreservation, Dimethyl sulfoxide, Freezing, Hematopoietic stem cells, Storage",
author = "Hornberger, {Kathlyn M} and Guanglin Yu and McKenna, {David H} and Allison Hubel",
year = "2019",
month = "6",
day = "1",
doi = "10.1159/000496068",
language = "English (US)",
volume = "46",
pages = "188--196",
journal = "Transfusion Medicine and Hemotherapy",
issn = "1660-3796",
publisher = "S. Karger AG",
number = "3",

}

TY - JOUR

T1 - Cryopreservation of Hematopoietic Stem Cells

T2 - Emerging Assays, Cryoprotectant Agents, and Technology to Improve Outcomes

AU - Hornberger, Kathlyn M

AU - Yu, Guanglin

AU - McKenna, David H

AU - Hubel, Allison

PY - 2019/6/1

Y1 - 2019/6/1

N2 - Hematopoietic stem cell (HSC) therapy is widely used to treat a growing number of hematological and non-hematological diseases. Cryopreservation of HSCs allows for cells to be transported from the site of processing to the site of clinical use, creates a larger window of time in which cells can be administered to patients, and allows sufficient time for quality control and regulatory testing. Currently, HSCs and other cell therapies conform to the same cryopreservation techniques as cells used for research purposes: cells are cryopreserved in dimethyl sulfoxide (DMSO) at a slow cooling rate. As a result, HSC therapy can result in numerous adverse symptoms in patients due to the infusion of DMSO. Efforts are being made to improve the cryopreservation of HSCs for clinical use. This review discusses advances in the cryopreservation of HSCs from 2007 to the present. The preclinical development of new cryoprotectants and new technology to eliminate cryoprotectants after thawing are discussed in detail. Additional cryopreservation considerations are included, such as cooling rate, storage temperature, and cell concentration. Preclinical cell assessment and quality control are discussed, as well as clinical studies from the past decade that focus on new cryopreservation protocols to improve patient outcomes.

AB - Hematopoietic stem cell (HSC) therapy is widely used to treat a growing number of hematological and non-hematological diseases. Cryopreservation of HSCs allows for cells to be transported from the site of processing to the site of clinical use, creates a larger window of time in which cells can be administered to patients, and allows sufficient time for quality control and regulatory testing. Currently, HSCs and other cell therapies conform to the same cryopreservation techniques as cells used for research purposes: cells are cryopreserved in dimethyl sulfoxide (DMSO) at a slow cooling rate. As a result, HSC therapy can result in numerous adverse symptoms in patients due to the infusion of DMSO. Efforts are being made to improve the cryopreservation of HSCs for clinical use. This review discusses advances in the cryopreservation of HSCs from 2007 to the present. The preclinical development of new cryoprotectants and new technology to eliminate cryoprotectants after thawing are discussed in detail. Additional cryopreservation considerations are included, such as cooling rate, storage temperature, and cell concentration. Preclinical cell assessment and quality control are discussed, as well as clinical studies from the past decade that focus on new cryopreservation protocols to improve patient outcomes.

KW - Cryopreservation

KW - Dimethyl sulfoxide

KW - Freezing

KW - Hematopoietic stem cells

KW - Storage

UR - http://www.scopus.com/inward/record.url?scp=85061344021&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061344021&partnerID=8YFLogxK

U2 - 10.1159/000496068

DO - 10.1159/000496068

M3 - Review article

VL - 46

SP - 188

EP - 196

JO - Transfusion Medicine and Hemotherapy

JF - Transfusion Medicine and Hemotherapy

SN - 1660-3796

IS - 3

ER -